UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of Registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File No.) |
(IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities Registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement
Omnibus Amendment Agreement
As previously disclosed, on May 20, 2024, Q/C Technologies, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Series G Purchase Agreement”) with certain accredited investors (the “Holders”) pursuant to which the Company issued and sold to the Holders in a private placement (i) shares of the Company’s Series G convertible preferred stock, par value $0.001 per share (the “Series G Preferred Stock”), (ii) certain warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), with a term of five (5) years from the date of issuance (the “Series G Long-Term Warrants”), and (iii) warrants to purchase shares of the Company’s Common Stock, with an initial term of eighteen (18) months from the date of issuance. The terms of the Series G Preferred Stock are set forth in the Certificate of Designations of Series G Preferred Stock filed with the Secretary of State of the State of Delaware (the “Secretary of State”) on May 21, 2024 (as amended, the “Series G Certificate of Designations”).
As previously disclosed, on September 2, 2025, the Company entered into a Securities Purchase Agreement (the “Series H Purchase Agreement”) with the Holders pursuant to which the Company issued and sold to the Holders (i) shares of the Company’s Series H Convertible Preferred Stock, par value $0.001 per share (the “Series H Preferred Stock”), and (ii) accompanying warrants to purchase shares of Common Stock (the “Series H Warrants”). The terms of the Series H Preferred Stock are set forth in the Certificate of Designations of Series H Convertible Preferred Stock filed with the Secretary of State on September 3, 2025 (as amended, the “Series H Certificate of Designations”).
On November 20, 2026, the Company entered into an Omnibus Amendment Agreement (the “Omnibus Agreement”) with PharmaCyte Biotech, Inc. (“PharmaCyte”), which holds at least a majority of the outstanding shares of each of the Series G Preferred Stock and the Series H Preferred Stock and thereby constitutes the Required Holders (as defined under each of the Series G Certificate of Designations and the Series H Certificate of Designations). Pursuant to the Omnibus Agreement, PharmaCyte agreed to amend (i) the Series G Certificate of Designations by filing a Certificate of Amendment (the “Series G Amendment”) with the Secretary of State, (ii) the Series H Certificate of Designations by filing a Certificate of Amendment (the “Series H Amendment”) with the Secretary of State, and (iii) the Series G Long-Term Warrants held by PharmaCyte to amend the amendment provisions and the beneficial ownership limitation provisions contained therein.
Each of the Series G Amendment and the Series H Amendment amends the amendment provisions as set forth therein and amends the beneficial ownership limitations with respect to PharmaCyte. On November 20, 2026, the Company filed the Series G Amendment and the Series H Amendment with the Secretary of State, thereby amending the Series G Certificate of Designations and the Series H Certificate of Designations, respectively. Each of the Series G Amendment and the Series H Amendment became effective with the Secretary of State upon filing.
The foregoing descriptions of the Omnibus Agreement, the Series G Amendment, and the Series H Amendment do not purport to be complete and are qualified in their entirety by reference to the full text of each such document, copies of which are filed as Exhibit 10.1, Exhibit 3.1 and Exhibit 3.2, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.
Item 3.03 Material Modification to Rights of Security Holders
The matters described in Item 1.01 of this Current Report on Form 8-K related to the Omnibus Agreement, the Series G Amendment and the Series H Amendment are incorporated herein by reference.
As previously disclosed in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 16, 2026, the Company entered into a Consent and Warrant Exchange Agreement on November 15, 2026 (the “Consent Agreement”) with PharmaCyte. Under the Consent Agreement, PharmaCyte consented to an amendment to the Series H Certificate of Designations that extends the maturity date of the Series H Preferred Stock from March 2, 2027 to September 2, 2027 (the “Series H Maturity Amendment”). On November 20, 2026, the Company filed the Series H Maturity Amendment with the Secretary of State.
The foregoing description of the Series H Maturity Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Series H Maturity Amendment, a copy of which is filed as Exhibit 3.3 to this Current Report on Form 8-K and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
| Exhibit Number | Description | |
| 3.1 | Certificate of Amendment of Certificate of Designations of Series G Convertible Preferred Stock (beneficial ownership limitation). | |
| 3.2 | Certificate of Amendment of Certificate of Designations of Series H Convertible Preferred Stock (beneficial ownership limitation). | |
| 3.3 | Certificate of Amendment of Certificate of Designations of Series H Convertible Preferred Stock (maturity date amendment). | |
| 10.1 | Omnibus Amendment Agreement, dated as of November 20, 2026, by and between Q/C Technologies, Inc. and PharmaCyte Biotech, Inc. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Q/C TECHNOLOGIES, INC. | ||
| Date: November 20, 2026 | By: | /s/ Joshua Silverman |
| Name: | Joshua Silverman | |
| Title: | Executive Chairman | |